nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ERBB2—malignant glioma	0.476	0.679	CbGaD
Afatinib—EGFR—malignant glioma	0.225	0.321	CbGaD
Afatinib—Disease progression—Carmustine—malignant glioma	0.00498	0.111	CcSEcCtD
Afatinib—Pulmonary toxicity—Carmustine—malignant glioma	0.00479	0.107	CcSEcCtD
Afatinib—PHKG2—brainstem—malignant glioma	0.00241	0.0437	CbGeAlD
Afatinib—ERBB2—embryo—malignant glioma	0.00236	0.0428	CbGeAlD
Afatinib—ERBB4—embryo—malignant glioma	0.00236	0.0428	CbGeAlD
Afatinib—ERBB4—brainstem—malignant glioma	0.00216	0.0393	CbGeAlD
Afatinib—DYRK1A—brainstem—malignant glioma	0.00208	0.0378	CbGeAlD
Afatinib—ERBB4—telencephalon—malignant glioma	0.00192	0.0348	CbGeAlD
Afatinib—DYRK1A—telencephalon—malignant glioma	0.00185	0.0335	CbGeAlD
Afatinib—PHKG2—medulla oblongata—malignant glioma	0.00168	0.0304	CbGeAlD
Afatinib—EGFR—telencephalon—malignant glioma	0.00163	0.0295	CbGeAlD
Afatinib—Interstitial lung disease—Carmustine—malignant glioma	0.00154	0.0343	CcSEcCtD
Afatinib—ERBB4—medulla oblongata—malignant glioma	0.00151	0.0274	CbGeAlD
Afatinib—Interstitial lung disease—Temozolomide—malignant glioma	0.00148	0.0331	CcSEcCtD
Afatinib—IRAK1—telencephalon—malignant glioma	0.00144	0.0261	CbGeAlD
Afatinib—ERBB4—midbrain—malignant glioma	0.00138	0.025	CbGeAlD
Afatinib—ERBB4—spinal cord—malignant glioma	0.00134	0.0244	CbGeAlD
Afatinib—HIPK4—brain—malignant glioma	0.00126	0.0229	CbGeAlD
Afatinib—EPHA6—central nervous system—malignant glioma	0.00126	0.0228	CbGeAlD
Afatinib—Vandetanib—KDR—malignant glioma	0.00124	0.308	CrCbGaD
Afatinib—PHKG2—central nervous system—malignant glioma	0.00121	0.022	CbGeAlD
Afatinib—PHKG2—cerebellum—malignant glioma	0.00119	0.0215	CbGeAlD
Afatinib—ERBB2—central nervous system—malignant glioma	0.00109	0.0198	CbGeAlD
Afatinib—ERBB4—central nervous system—malignant glioma	0.00109	0.0198	CbGeAlD
Afatinib—ERBB4—cerebellum—malignant glioma	0.00107	0.0194	CbGeAlD
Afatinib—ERBB2—cerebellum—malignant glioma	0.00107	0.0194	CbGeAlD
Afatinib—Vandetanib—VEGFA—malignant glioma	0.00105	0.261	CrCbGaD
Afatinib—DYRK1A—central nervous system—malignant glioma	0.00105	0.0191	CbGeAlD
Afatinib—IRAK1—midbrain—malignant glioma	0.00103	0.0187	CbGeAlD
Afatinib—DYRK1A—cerebellum—malignant glioma	0.00103	0.0186	CbGeAlD
Afatinib—EPHA6—brain—malignant glioma	0.000999	0.0181	CbGeAlD
Afatinib—ABL1—embryo—malignant glioma	0.000989	0.0179	CbGeAlD
Afatinib—Dry eye—Temozolomide—malignant glioma	0.000971	0.0217	CcSEcCtD
Afatinib—PHKG2—brain—malignant glioma	0.000963	0.0175	CbGeAlD
Afatinib—Sepsis—Carmustine—malignant glioma	0.000944	0.0211	CcSEcCtD
Afatinib—ABL1—brainstem—malignant glioma	0.000906	0.0164	CbGeAlD
Afatinib—EGFR—cerebellum—malignant glioma	0.000904	0.0164	CbGeAlD
Afatinib—Vandetanib—EGFR—malignant glioma	0.000889	0.221	CrCbGaD
Afatinib—ABL1—retina—malignant glioma	0.000874	0.0159	CbGeAlD
Afatinib—ERBB2—brain—malignant glioma	0.000866	0.0157	CbGeAlD
Afatinib—ERBB4—brain—malignant glioma	0.000866	0.0157	CbGeAlD
Afatinib—Gefitinib—EGFR—malignant glioma	0.000844	0.21	CrCbGaD
Afatinib—DYRK1A—brain—malignant glioma	0.000834	0.0151	CbGeAlD
Afatinib—ABL1—telencephalon—malignant glioma	0.000804	0.0146	CbGeAlD
Afatinib—IRAK1—cerebellum—malignant glioma	0.000798	0.0145	CbGeAlD
Afatinib—EGFR—brain—malignant glioma	0.000734	0.0133	CbGeAlD
Afatinib—Hypokalaemia—Carmustine—malignant glioma	0.000718	0.016	CcSEcCtD
Afatinib—Dehydration—Temozolomide—malignant glioma	0.000709	0.0158	CcSEcCtD
Afatinib—Dry skin—Temozolomide—malignant glioma	0.000699	0.0156	CcSEcCtD
Afatinib—Hypokalaemia—Temozolomide—malignant glioma	0.000694	0.0155	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000687	0.0153	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000673	0.015	CcSEcCtD
Afatinib—IRAK1—brain—malignant glioma	0.000648	0.0118	CbGeAlD
Afatinib—ABL1—medulla oblongata—malignant glioma	0.000632	0.0115	CbGeAlD
Afatinib—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000613	0.0137	CcSEcCtD
Afatinib—Pneumonia—Carmustine—malignant glioma	0.000612	0.0137	CcSEcCtD
Afatinib—Renal failure—Carmustine—malignant glioma	0.000598	0.0133	CcSEcCtD
Afatinib—Weight decreased—Temozolomide—malignant glioma	0.000597	0.0133	CcSEcCtD
Afatinib—Stomatitis—Carmustine—malignant glioma	0.000593	0.0132	CcSEcCtD
Afatinib—Urinary tract infection—Carmustine—malignant glioma	0.000591	0.0132	CcSEcCtD
Afatinib—Pneumonia—Temozolomide—malignant glioma	0.000591	0.0132	CcSEcCtD
Afatinib—Infestation—Temozolomide—malignant glioma	0.000588	0.0131	CcSEcCtD
Afatinib—Infestation NOS—Temozolomide—malignant glioma	0.000588	0.0131	CcSEcCtD
Afatinib—ABL1—midbrain—malignant glioma	0.000578	0.0105	CbGeAlD
Afatinib—Stomatitis—Temozolomide—malignant glioma	0.000573	0.0128	CcSEcCtD
Afatinib—Urinary tract infection—Temozolomide—malignant glioma	0.000571	0.0128	CcSEcCtD
Afatinib—ABL1—spinal cord—malignant glioma	0.000564	0.0102	CbGeAlD
Afatinib—Hepatobiliary disease—Temozolomide—malignant glioma	0.000556	0.0124	CcSEcCtD
Afatinib—Connective tissue disorder—Carmustine—malignant glioma	0.000537	0.012	CcSEcCtD
Afatinib—Urinary tract disorder—Temozolomide—malignant glioma	0.000521	0.0116	CcSEcCtD
Afatinib—Connective tissue disorder—Temozolomide—malignant glioma	0.000519	0.0116	CcSEcCtD
Afatinib—Urethral disorder—Temozolomide—malignant glioma	0.000517	0.0115	CcSEcCtD
Afatinib—ABCB1—blood vessel—malignant glioma	0.000516	0.00936	CbGeAlD
Afatinib—Eye disorder—Carmustine—malignant glioma	0.00051	0.0114	CcSEcCtD
Afatinib—ABCG2—telencephalon—malignant glioma	0.000507	0.0092	CbGeAlD
Afatinib—Eye disorder—Temozolomide—malignant glioma	0.000493	0.011	CcSEcCtD
Afatinib—Alopecia—Carmustine—malignant glioma	0.000483	0.0108	CcSEcCtD
Afatinib—Mental disorder—Carmustine—malignant glioma	0.000478	0.0107	CcSEcCtD
Afatinib—Mediastinal disorder—Temozolomide—malignant glioma	0.000476	0.0106	CcSEcCtD
Afatinib—Malnutrition—Carmustine—malignant glioma	0.000475	0.0106	CcSEcCtD
Afatinib—Alopecia—Temozolomide—malignant glioma	0.000466	0.0104	CcSEcCtD
Afatinib—Mental disorder—Temozolomide—malignant glioma	0.000462	0.0103	CcSEcCtD
Afatinib—Back pain—Carmustine—malignant glioma	0.00046	0.0103	CcSEcCtD
Afatinib—Malnutrition—Temozolomide—malignant glioma	0.000459	0.0103	CcSEcCtD
Afatinib—ABL1—central nervous system—malignant glioma	0.000457	0.0083	CbGeAlD
Afatinib—Dysgeusia—Temozolomide—malignant glioma	0.00045	0.01	CcSEcCtD
Afatinib—ABL1—cerebellum—malignant glioma	0.000447	0.00811	CbGeAlD
Afatinib—Back pain—Temozolomide—malignant glioma	0.000444	0.00992	CcSEcCtD
Afatinib—Cough—Temozolomide—malignant glioma	0.000401	0.00895	CcSEcCtD
Afatinib—ABCG2—medulla oblongata—malignant glioma	0.000399	0.00723	CbGeAlD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000388	0.00867	CcSEcCtD
Afatinib—Infection—Carmustine—malignant glioma	0.000385	0.0086	CcSEcCtD
Afatinib—Infection—Temozolomide—malignant glioma	0.000372	0.00831	CcSEcCtD
Afatinib—Nervous system disorder—Temozolomide—malignant glioma	0.000368	0.00821	CcSEcCtD
Afatinib—ABCG2—midbrain—malignant glioma	0.000364	0.00661	CbGeAlD
Afatinib—Skin disorder—Temozolomide—malignant glioma	0.000364	0.00813	CcSEcCtD
Afatinib—ABL1—brain—malignant glioma	0.000363	0.00659	CbGeAlD
Afatinib—ABCG2—spinal cord—malignant glioma	0.000355	0.00645	CbGeAlD
Afatinib—Insomnia—Carmustine—malignant glioma	0.000351	0.00783	CcSEcCtD
Afatinib—Dyspnoea—Carmustine—malignant glioma	0.000346	0.00772	CcSEcCtD
Afatinib—Insomnia—Temozolomide—malignant glioma	0.000339	0.00757	CcSEcCtD
Afatinib—Decreased appetite—Carmustine—malignant glioma	0.000337	0.00753	CcSEcCtD
Afatinib—Gastrointestinal disorder—Carmustine—malignant glioma	0.000335	0.00748	CcSEcCtD
Afatinib—Dyspnoea—Temozolomide—malignant glioma	0.000334	0.00746	CcSEcCtD
Afatinib—Constipation—Carmustine—malignant glioma	0.000332	0.0074	CcSEcCtD
Afatinib—Dyspepsia—Temozolomide—malignant glioma	0.00033	0.00737	CcSEcCtD
Afatinib—Decreased appetite—Temozolomide—malignant glioma	0.000326	0.00727	CcSEcCtD
Afatinib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000324	0.00722	CcSEcCtD
Afatinib—Fatigue—Temozolomide—malignant glioma	0.000323	0.00721	CcSEcCtD
Afatinib—Constipation—Temozolomide—malignant glioma	0.000321	0.00716	CcSEcCtD
Afatinib—ABCB1—embryo—malignant glioma	0.000308	0.00558	CbGeAlD
Afatinib—Body temperature increased—Carmustine—malignant glioma	0.000307	0.00685	CcSEcCtD
Afatinib—Body temperature increased—Temozolomide—malignant glioma	0.000296	0.00661	CcSEcCtD
Afatinib—ABCG2—cerebellum—malignant glioma	0.000282	0.00511	CbGeAlD
Afatinib—Asthenia—Carmustine—malignant glioma	0.000278	0.00621	CcSEcCtD
Afatinib—ABCB1—retina—malignant glioma	0.000272	0.00493	CbGeAlD
Afatinib—Asthenia—Temozolomide—malignant glioma	0.000269	0.006	CcSEcCtD
Afatinib—Diarrhoea—Carmustine—malignant glioma	0.000265	0.00592	CcSEcCtD
Afatinib—Pruritus—Temozolomide—malignant glioma	0.000265	0.00592	CcSEcCtD
Afatinib—Dizziness—Carmustine—malignant glioma	0.000257	0.00573	CcSEcCtD
Afatinib—Diarrhoea—Temozolomide—malignant glioma	0.000257	0.00573	CcSEcCtD
Afatinib—ABCB1—telencephalon—malignant glioma	0.00025	0.00454	CbGeAlD
Afatinib—Dizziness—Temozolomide—malignant glioma	0.000248	0.00553	CcSEcCtD
Afatinib—Vomiting—Carmustine—malignant glioma	0.000247	0.00551	CcSEcCtD
Afatinib—Rash—Carmustine—malignant glioma	0.000245	0.00546	CcSEcCtD
Afatinib—Dermatitis—Carmustine—malignant glioma	0.000244	0.00545	CcSEcCtD
Afatinib—Headache—Carmustine—malignant glioma	0.000243	0.00542	CcSEcCtD
Afatinib—Vomiting—Temozolomide—malignant glioma	0.000238	0.00532	CcSEcCtD
Afatinib—Rash—Temozolomide—malignant glioma	0.000236	0.00528	CcSEcCtD
Afatinib—Dermatitis—Temozolomide—malignant glioma	0.000236	0.00527	CcSEcCtD
Afatinib—Headache—Temozolomide—malignant glioma	0.000235	0.00524	CcSEcCtD
Afatinib—Nausea—Carmustine—malignant glioma	0.00023	0.00514	CcSEcCtD
Afatinib—ABCG2—brain—malignant glioma	0.000229	0.00415	CbGeAlD
Afatinib—Nausea—Temozolomide—malignant glioma	0.000223	0.00497	CcSEcCtD
Afatinib—ABCB1—medulla oblongata—malignant glioma	0.000197	0.00357	CbGeAlD
Afatinib—ABCB1—midbrain—malignant glioma	0.00018	0.00326	CbGeAlD
Afatinib—ABCB1—spinal cord—malignant glioma	0.000175	0.00318	CbGeAlD
Afatinib—ABCB1—central nervous system—malignant glioma	0.000142	0.00258	CbGeAlD
Afatinib—ABCB1—cerebellum—malignant glioma	0.000139	0.00252	CbGeAlD
Afatinib—ABCB1—brain—malignant glioma	0.000113	0.00205	CbGeAlD
Afatinib—ERBB4—Signaling Pathways—MMP9—malignant glioma	4.99e-06	2.55e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HES1—malignant glioma	4.98e-06	2.55e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTPN11—malignant glioma	4.98e-06	2.54e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KRAS—malignant glioma	4.97e-06	2.54e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PTEN—malignant glioma	4.96e-06	2.54e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NCOR1—malignant glioma	4.96e-06	2.53e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—AKT1—malignant glioma	4.94e-06	2.53e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—BRAF—malignant glioma	4.94e-06	2.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTK2—malignant glioma	4.89e-06	2.5e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—RAF1—malignant glioma	4.89e-06	2.5e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—PIK3CA—malignant glioma	4.89e-06	2.5e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—malignant glioma	4.87e-06	2.49e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—AKT1—malignant glioma	4.85e-06	2.48e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CD—malignant glioma	4.84e-06	2.47e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CD—malignant glioma	4.82e-06	2.47e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT2—malignant glioma	4.81e-06	2.46e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HES1—malignant glioma	4.8e-06	2.46e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—FGF2—malignant glioma	4.79e-06	2.45e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KRAS—malignant glioma	4.79e-06	2.45e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NCOR1—malignant glioma	4.78e-06	2.44e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CB—malignant glioma	4.77e-06	2.44e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KRAS—malignant glioma	4.77e-06	2.44e-05	CbGpPWpGaD
Afatinib—LCK—Disease—BRAF—malignant glioma	4.76e-06	2.43e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PDGFRA—malignant glioma	4.75e-06	2.43e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—malignant glioma	4.73e-06	2.42e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1B—malignant glioma	4.71e-06	2.41e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTT1—malignant glioma	4.7e-06	2.4e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL2—malignant glioma	4.69e-06	2.4e-05	CbGpPWpGaD
Afatinib—LCK—Disease—AKT2—malignant glioma	4.63e-06	2.37e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FGF2—malignant glioma	4.63e-06	2.37e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CD—malignant glioma	4.62e-06	2.36e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—FGF2—malignant glioma	4.62e-06	2.36e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SPP1—malignant glioma	4.61e-06	2.36e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KRAS—malignant glioma	4.6e-06	2.35e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCL8—malignant glioma	4.59e-06	2.35e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—malignant glioma	4.58e-06	2.34e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PDGFRA—malignant glioma	4.57e-06	2.34e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—PIK3CA—malignant glioma	4.56e-06	2.33e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	4.56e-06	2.33e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—malignant glioma	4.55e-06	2.33e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—BCL2—malignant glioma	4.55e-06	2.33e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CAV1—malignant glioma	4.51e-06	2.31e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STAT3—malignant glioma	4.51e-06	2.3e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IFNG—malignant glioma	4.51e-06	2.3e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—AKT1—malignant glioma	4.49e-06	2.3e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—malignant glioma	4.48e-06	2.29e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MDM2—malignant glioma	4.48e-06	2.29e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—RAF1—malignant glioma	4.47e-06	2.28e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CD—malignant glioma	4.45e-06	2.28e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STAT3—malignant glioma	4.44e-06	2.27e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SPP1—malignant glioma	4.44e-06	2.27e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—AKT1—malignant glioma	4.43e-06	2.26e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—FGF2—malignant glioma	4.42e-06	2.26e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—ERBB2—malignant glioma	4.42e-06	2.26e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PTEN—malignant glioma	4.41e-06	2.25e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS1—malignant glioma	4.4e-06	2.25e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PIK3CA—malignant glioma	4.4e-06	2.25e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—BCL2—malignant glioma	4.38e-06	2.24e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL2—malignant glioma	4.38e-06	2.24e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PIK3CA—malignant glioma	4.38e-06	2.24e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TERT—malignant glioma	4.37e-06	2.23e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—AKT1—malignant glioma	4.36e-06	2.23e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CB—malignant glioma	4.36e-06	2.23e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IFNG—malignant glioma	4.34e-06	2.22e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MDM2—malignant glioma	4.33e-06	2.22e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KRAS—malignant glioma	4.33e-06	2.21e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MDM2—malignant glioma	4.32e-06	2.21e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RAF1—malignant glioma	4.32e-06	2.21e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—RAF1—malignant glioma	4.31e-06	2.2e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ERBB2—malignant glioma	4.27e-06	2.18e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PDGFB—malignant glioma	4.26e-06	2.18e-05	CbGpPWpGaD
Afatinib—LCK—Disease—FGF2—malignant glioma	4.26e-06	2.18e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ERBB2—malignant glioma	4.26e-06	2.18e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—AKT1—malignant glioma	4.26e-06	2.18e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGFR1—malignant glioma	4.24e-06	2.17e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PIK3CA—malignant glioma	4.22e-06	2.16e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—AKT1—malignant glioma	4.22e-06	2.16e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CB—malignant glioma	4.22e-06	2.16e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TERT—malignant glioma	4.21e-06	2.15e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CB—malignant glioma	4.2e-06	2.15e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—malignant glioma	4.19e-06	2.14e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HIF1A—malignant glioma	4.18e-06	2.14e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—malignant glioma	4.15e-06	2.12e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MDM2—malignant glioma	4.14e-06	2.12e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—malignant glioma	4.13e-06	2.11e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—RAF1—malignant glioma	4.12e-06	2.11e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CG—malignant glioma	4.11e-06	2.1e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PDGFB—malignant glioma	4.11e-06	2.1e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—malignant glioma	4.1e-06	2.09e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—BCHE—malignant glioma	4.09e-06	2.09e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGFR1—malignant glioma	4.09e-06	2.09e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—malignant glioma	4.09e-06	2.09e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB2—malignant glioma	4.08e-06	2.09e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL8—malignant glioma	4.05e-06	2.07e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC5A5—malignant glioma	4.04e-06	2.07e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CAV1—malignant glioma	4.04e-06	2.07e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—malignant glioma	4.04e-06	2.06e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CB—malignant glioma	4.03e-06	2.06e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HIF1A—malignant glioma	4.03e-06	2.06e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1B—malignant glioma	4.02e-06	2.06e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—malignant glioma	4.01e-06	2.05e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KDR—malignant glioma	3.99e-06	2.04e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—malignant glioma	3.99e-06	2.04e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—malignant glioma	3.99e-06	2.04e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MDM2—malignant glioma	3.99e-06	2.04e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—malignant glioma	3.98e-06	2.03e-05	CbGpPWpGaD
Afatinib—LCK—Disease—RAF1—malignant glioma	3.97e-06	2.03e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARG—malignant glioma	3.97e-06	2.03e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—malignant glioma	3.94e-06	2.02e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB2—malignant glioma	3.93e-06	2.01e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CAV1—malignant glioma	3.89e-06	1.99e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CB—malignant glioma	3.88e-06	1.98e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—malignant glioma	3.88e-06	1.98e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—malignant glioma	3.87e-06	1.98e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—malignant glioma	3.87e-06	1.98e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—malignant glioma	3.87e-06	1.98e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—malignant glioma	3.86e-06	1.97e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KDR—malignant glioma	3.85e-06	1.97e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—F2—malignant glioma	3.85e-06	1.97e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FN1—malignant glioma	3.85e-06	1.97e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—malignant glioma	3.85e-06	1.97e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—malignant glioma	3.81e-06	1.95e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BAD—malignant glioma	3.8e-06	1.94e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTEN—malignant glioma	3.77e-06	1.93e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOTCH1—malignant glioma	3.76e-06	1.92e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—malignant glioma	3.73e-06	1.91e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	3.72e-06	1.9e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—F2—malignant glioma	3.71e-06	1.89e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FN1—malignant glioma	3.71e-06	1.89e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CD80—malignant glioma	3.69e-06	1.88e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CG—malignant glioma	3.68e-06	1.88e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APC—malignant glioma	3.68e-06	1.88e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—malignant glioma	3.67e-06	1.87e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BAD—malignant glioma	3.66e-06	1.87e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTEN—malignant glioma	3.64e-06	1.86e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EGF—malignant glioma	3.64e-06	1.86e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PTEN—malignant glioma	3.63e-06	1.86e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOTCH1—malignant glioma	3.63e-06	1.85e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTPN11—malignant glioma	3.62e-06	1.85e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CD—malignant glioma	3.61e-06	1.85e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—malignant glioma	3.59e-06	1.84e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—malignant glioma	3.58e-06	1.83e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—malignant glioma	3.58e-06	1.83e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—malignant glioma	3.56e-06	1.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CD80—malignant glioma	3.55e-06	1.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CG—malignant glioma	3.55e-06	1.81e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APC—malignant glioma	3.55e-06	1.81e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGF—malignant glioma	3.51e-06	1.79e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—malignant glioma	3.5e-06	1.79e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTPN11—malignant glioma	3.48e-06	1.78e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTEN—malignant glioma	3.48e-06	1.78e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BRAF—malignant glioma	3.46e-06	1.77e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—malignant glioma	3.45e-06	1.76e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—malignant glioma	3.44e-06	1.76e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—malignant glioma	3.39e-06	1.73e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—malignant glioma	3.39e-06	1.73e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—malignant glioma	3.37e-06	1.72e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT2—malignant glioma	3.37e-06	1.72e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTEN—malignant glioma	3.35e-06	1.71e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BRAF—malignant glioma	3.33e-06	1.7e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—malignant glioma	3.29e-06	1.68e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—malignant glioma	3.26e-06	1.67e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTP1—malignant glioma	3.26e-06	1.66e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—malignant glioma	3.25e-06	1.66e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—malignant glioma	3.25e-06	1.66e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT2—malignant glioma	3.24e-06	1.66e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CD—malignant glioma	3.24e-06	1.65e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAT—malignant glioma	3.17e-06	1.62e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—malignant glioma	3.17e-06	1.62e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CB—malignant glioma	3.15e-06	1.61e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—malignant glioma	3.12e-06	1.59e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CD—malignant glioma	3.12e-06	1.59e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—malignant glioma	3.11e-06	1.59e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—malignant glioma	3.11e-06	1.59e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGF2—malignant glioma	3.1e-06	1.58e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—malignant glioma	3.03e-06	1.55e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—malignant glioma	3e-06	1.53e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NCOR1—malignant glioma	2.99e-06	1.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGF2—malignant glioma	2.99e-06	1.53e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—malignant glioma	2.96e-06	1.51e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—malignant glioma	2.95e-06	1.51e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—malignant glioma	2.91e-06	1.49e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—malignant glioma	2.9e-06	1.49e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MDM2—malignant glioma	2.9e-06	1.48e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—malignant glioma	2.89e-06	1.48e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—malignant glioma	2.89e-06	1.48e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RAF1—malignant glioma	2.89e-06	1.48e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—malignant glioma	2.86e-06	1.46e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB2—malignant glioma	2.86e-06	1.46e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CB—malignant glioma	2.82e-06	1.44e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—malignant glioma	2.8e-06	1.43e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MDM2—malignant glioma	2.79e-06	1.43e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—malignant glioma	2.79e-06	1.43e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—malignant glioma	2.79e-06	1.42e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RAF1—malignant glioma	2.78e-06	1.42e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB2—malignant glioma	2.75e-06	1.41e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—malignant glioma	2.73e-06	1.39e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTEN—malignant glioma	2.72e-06	1.39e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CB—malignant glioma	2.72e-06	1.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—malignant glioma	2.71e-06	1.39e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—malignant glioma	2.67e-06	1.37e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—malignant glioma	2.66e-06	1.36e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—malignant glioma	2.61e-06	1.34e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—malignant glioma	2.59e-06	1.33e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—malignant glioma	2.59e-06	1.32e-05	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—malignant glioma	2.57e-06	1.32e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—malignant glioma	2.57e-06	1.31e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—malignant glioma	2.56e-06	1.31e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—malignant glioma	2.54e-06	1.3e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—malignant glioma	2.5e-06	1.28e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—malignant glioma	2.5e-06	1.28e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—malignant glioma	2.49e-06	1.27e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—malignant glioma	2.45e-06	1.25e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—malignant glioma	2.45e-06	1.25e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAV1—malignant glioma	2.44e-06	1.25e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTEN—malignant glioma	2.44e-06	1.25e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—malignant glioma	2.38e-06	1.22e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—malignant glioma	2.37e-06	1.21e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—malignant glioma	2.36e-06	1.21e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTEN—malignant glioma	2.35e-06	1.2e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CG—malignant glioma	2.22e-06	1.14e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—malignant glioma	2.2e-06	1.13e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—malignant glioma	2.18e-06	1.11e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—malignant glioma	2.17e-06	1.11e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARG—malignant glioma	2.14e-06	1.1e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—malignant glioma	2.12e-06	1.08e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—malignant glioma	2.1e-06	1.07e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—malignant glioma	2.1e-06	1.07e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—malignant glioma	2.09e-06	1.07e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—malignant glioma	2.02e-06	1.04e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—malignant glioma	2.01e-06	1.03e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CD—malignant glioma	1.95e-06	9.98e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—malignant glioma	1.95e-06	9.98e-06	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—malignant glioma	1.93e-06	9.88e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—malignant glioma	1.92e-06	9.81e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—malignant glioma	1.91e-06	9.76e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—malignant glioma	1.87e-06	9.57e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—malignant glioma	1.8e-06	9.22e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—malignant glioma	1.72e-06	8.79e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CB—malignant glioma	1.7e-06	8.7e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—malignant glioma	1.69e-06	8.62e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—malignant glioma	1.66e-06	8.5e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—malignant glioma	1.66e-06	8.47e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—malignant glioma	1.6e-06	8.19e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—malignant glioma	1.57e-06	8.02e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTEN—malignant glioma	1.47e-06	7.52e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—malignant glioma	1.4e-06	7.18e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—malignant glioma	1.35e-06	6.92e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—malignant glioma	1.04e-06	5.3e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—malignant glioma	8.48e-07	4.33e-06	CbGpPWpGaD
